This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety in patients with acute coronary syndrome in Fuwai Hospital.
Study Type
OBSERVATIONAL
Enrollment
1,200
Fuwai Hospital
Beijing, Beijing Municipality, China
RECRUITINGNumber of participants with switching between clopidogrel and ticagrelor
Time frame: 12 months
Number of participants with switching between clopidogrel and ticagrelor without a reloading dose
Time frame: 12 months
Number of Participants with discontinuation of P2Y12 receptor antagonist
Time frame: 12 months
Number of Participants with ticagrelor combined with other anticoagulants
Time frame: 12 months
Cardiovascular Mortality, Myocardial Infarction(MI), Ischemic Stoke
composite incidence Myocardial infarction is defined and subclassified in accordance with ACC/AHA/ESC third universal definition of myocardial infarction Ischemic stroke: an acute episode of focal cerebral, spinal, or retinal dysfunction caused by infarction, defined by at least one of the following: 1. Pathological, imaging, or other objective evidence of acute, focal cerebral, spinal, or retinal ischemic injury in a defined vascular distribution 2. Symptoms of acute cerebral, spinal, or retinal ischemic injury persisting ≧24 h, with other etiologies excluded Hemorrhage may be a consequence of ischemic stroke. In this situation, the stroke is an ischemic stroke with hemorrhagic transformation and not a hemorrhagic stroke.
Time frame: 12 months
Number of bleeding event will be recorded (defined in accordance with PLATO definition)
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.